Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia

Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia

Background. Working out of the second line chemotherapy of advanced gastric adenocarcinoma is a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). In April 2014, the FDA approved ramucirumab as a...

Full description

Bibliographic Details
Main Authors: N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, A. A. Fedenko
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-07-01
Series:Медицинский совет
Subjects:
advanced gastric cancer
second line treatment
ramucirumab
paclitaxel
Online Access:https://www.med-sovet.pro/jour/article/view/2530

Internet

https://www.med-sovet.pro/jour/article/view/2530

Similar Items